News Quantified

MRKR – marker therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Exploring High Growth Tech Stocks In The US December 2025 [Yahoo! Finance]

Exploring US High Growth Tech Stocks In December 2025 [Yahoo! Finance]

High Growth Tech Stocks To Watch In US December 2025 [Yahoo! Finance]

US High Growth Tech: 3 Stocks to Watch [Yahoo! Finance]

Marker Therapeutics (NASDAQ:MRKR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

H.C. WAINWRIGHT

H.C. WAINWRIGHT

Form 4 Marker Therapeutics, For: Nov 17 Filed by: Knobil Katharine

Form 4 Marker Therapeutics, For: Nov 17 Filed by: Eansor Norman David

Form 4 Marker Therapeutics, For: Nov 17 Filed by: ELMS STEVE

Form SCHEDULE 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.

Form SCHEDULE 13G/A Marker Therapeutics, Filed by: Alyeska Investment Group, L.P.

Top News Gainers

4/29 Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia 15.8%

8/15 Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs 15.0%

8/6 Marker Therapeutics Appoints Steve Elms to its Board of Directors 12.4%

4/10 FDA grants emergency authorization to two blood purification systems [MarketWatch] 10.9%

6/20 Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma 9.0%

5/9 Q1/2019 3/31/2019 EPS -0.120 ZacksConsensus N/A ActVsEst N/A - N/A 7.5%

3/2 Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million 6.7%

11/11 Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019 5.0%

8/8 Form 4 Marker Therapeutics, For: Aug 06 Filed by: ELMS STEVE 4.5%

8/13 TapImmune Inc. (NASDAQ: MRKR) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $16.00 price target on the stock. 4.4%

Top News Decliners

11/12 Form 10-Q Marker Therapeutics, For: Sep 30 -29.7%

7/19 Form 8-K Marker Therapeutics, For: Jul 19 -19.0%

3/12 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -16.8%

5/2 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. -8.2%

10/9 We Think Marker Therapeutics (NASDAQ:MRKR) Can Afford To Drive Business Growth [Yahoo! Finance News] -6.5%

7/20 Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR -5.8%

4/28 TapImmune Inc. (NASDAQ: MRKR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.7%

2/5 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.3%

2/11 Form 8-K Marker Therapeutics, For: Feb 11 -5.0%

4/21 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -5.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day